Literature DB >> 2857212

Reversibility of cyclosporin nephrotoxicity after three months' treatment.

J R Chapman, D Griffiths, N G Harding, P J Morris.   

Abstract

86 renal allograft recipients were randomly assigned to cyclosporin (Cy) for 90 days followed by azathioprine and prednisolone (Aza and P), or to Aza and P from day 0, as part of the second Oxford trial of short-term Cy use. All 62 patients whose grafts functioned for at least 120 days were included in this study. Serum creatinine was significantly higher in Cy-treated patients than in control patients from day 28 to day 90. Serum uric acid was also significantly higher in Cy-treated patients over the same period. Both creatinine and uric acid fell to the level of the control group after conversion to Aza and P. Serum uric acid was significantly higher for a given level of creatinine during Cy treatment than in either the control patients or the Cy-treated patients after their treatment had been changed to Aza and P. These data imply that Cy affects both the glomerular filtration rate and renal tubular function but that these effects are largely reversible.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2857212     DOI: 10.1016/s0140-6736(85)91902-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  17 in total

Review 1.  Gout in solid organ transplantation: a challenging clinical problem.

Authors:  Lisa Stamp; Martin Searle; John O'Donnell; Peter Chapman
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Recent advances in the epidemiology of gout.

Authors:  Kenneth G Saag; Ted R Mikuls
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

Review 3.  Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.

Authors:  Krishna M Karpe; Girish S Talaulikar; Giles D Walters
Journal:  Cochrane Database Syst Rev       Date:  2017-07-21

4.  New Organ Allocation System for Combined Liver-Kidney Transplants and the Availability of Kidneys for Transplant to Patients with Stage 4-5 CKD.

Authors:  William S Asch; Margaret J Bia
Journal:  Clin J Am Soc Nephrol       Date:  2016-12-27       Impact factor: 8.237

5.  Renal handling of magnesium in transplanted children under cyclosporin A treatment.

Authors:  F Krull; P F Hoyer; G Offner; J Brodehl
Journal:  Eur J Pediatr       Date:  1988-11       Impact factor: 3.183

Review 6.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

7.  Cyclosporine-induced nephrotoxicity in deoxycorticosterone-NaCl treated rats.

Authors:  J M Wyss; M S Mozaffari; P L St John; D R Abrahamson
Journal:  Int J Exp Pathol       Date:  1993-12       Impact factor: 1.925

8.  Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study.

Authors:  A W van Rijthoven; B A Dijkmans; H S Goei The; J Hermans; Z L Montnor-Beckers; P C Jacobs; A Cats
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

9.  Effect of cyclosporin on serum creatinine in patients with rheumatoid arthritis.

Authors:  B A Dijkmans; A W van Rijthoven; H S Goei The; Z L Montnor-Beckers; P C Jacobs; A Cats
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Cyclosporin and renal graft histology.

Authors:  A J d'Ardenne; M S Dunnill; J F Thompson; D McWhinnie; R F Wood; P J Morris
Journal:  J Clin Pathol       Date:  1986-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.